J Korean Cancer Assoc.  2001 Feb;33(1):77-83.

Expression of Cell Cycle Regulatory and Apoptosis-related Proteins in Etoposide-treated Human Skin Fibroblast

Affiliations
  • 1Department of Microbiology, College of Medicine, Seonam University, Namwon.
  • 2Department of Microbiology, School of Medicine, Keimyung University, Daegu, Korea.

Abstract

PURPOSE: This study was designed to investigate effect of the etoposide on expression of cell cycle regulatory proteins and apoptosis-related proteins in human skin fibroblast (HSF).
MATERIALS AND METHODS
HSF cells were treated with etoposide. After treatment, expression patterns of cell cycle regulatory proteins and apoptosis-related proteins were analyzed by using Immunoprecipitation-Western blot method and RT-PCR.
RESULTS
Immediately after etoposide treatment, E2F-1 was up- regulated following MDM2 down-regulation. After E2F-1 up-regulation, p53 and p21WAF1 level was markedly increased without or with mRNA up-regulation, respectively. Consistent with these results, cell cycles arrested in mainly G1 phase 24 hr after etoposide treatment. However, HSF cells progressed into apoptosis 72 hr after etoposide treatment. In this process, caspase-3 activation and Bax up-regulation were observed.
CONCLUSION
In early response of etoposide treatment, E2F-1 plays an important role in p53 accumulation through MDM2 down- regulation. The increased p53 induce an increase of p21WAF1 level through p21WAF1 mRNA up-regulation. However, after long term treatment of etoposide, HSF cells resulted in apoptotic cell death through caspase-3 activation and Bax up-regulation.

Keyword

E2F-1; Mouse double minute 2; p53 gene; p21WAF1; Etoposide

MeSH Terms

Apoptosis
Caspase 3
Cell Cycle Proteins
Cell Cycle*
Cell Death
Down-Regulation
Etoposide
Fibroblasts*
G1 Phase
Genes, p53
Humans*
RNA, Messenger
Skin*
Up-Regulation
Caspase 3
Cell Cycle Proteins
Etoposide
RNA, Messenger
Full Text Links
  • JKCA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr